Key Takeaways

Heavy R&D spending and persistent losses risk outpacing future revenue, pressuring margins despite a promising oncology pipeline.
Regulatory, pricing, and competitive pressures could limit profitability and hinder market adoption of innovative mRNA therapies.
Dependence on new oncology successes and regulatory approvals amid declining vaccine sales, high R&D costs, and geopolitical and competitive risks threatens sustained profitability and market position.

Catalysts

About BioNTech

A biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.What are the underlying business or industry changes driving this perspective?

While BioNTech's late-stage oncology pipeline, particularly BNT327 and mRNA cancer immunotherapies, could position the company for significant long-term growth as an innovative leader in cancer treatment, the heavy ongoing R&D investments—over 500 million euros per quarter—combined with persistent net losses (416 million euros in the latest quarter), raise concerns that future revenue streams may not be sufficient or timely enough to offset current and increasing expenses, thereby putting continued pressure on net margins and long-term earnings.
Although demographic trends such as rising global healthcare spending and the aging population support a larger addressable market for novel cancer therapies, there is significant risk that growing regulatory and governmental pressure to contain healthcare costs—especially for expensive, new mRNA or immuno-oncology drugs—could cap pricing and limit future revenue growth, undermining the potential profitability of BioNTech's new oncology products.
While mRNA technology adoption across mainstream medicine represents a transformative opportunity for BioNTech, broader acceptance remains uncertain amid growing resistance to mRNA-based vaccines and therapies in major markets, which could dampen future demand and restrict the company’s ability to fully capture anticipated revenue and market share.
Despite strong strategic partnerships, ongoing technology investments, and a robust cash position (15.9 billion euros at quarter end), the company faces escalating competition from established pharmaceutical giants and emerging biotech innovators in both the oncology and mRNA spaces, making it difficult to achieve projected commercial success or defend long-term operating margins as these markets become increasingly crowded.
Even though evolving regulatory frameworks theoretically support accelerated approval for innovative therapies, the sector faces heightened regulatory scrutiny and potential increases in development costs, particularly as safety and efficacy expectations grow for novel mRNA and ADC-based treatments, which could delay product launches and negatively impact the near
to mid-term revenue trajectory and earnings visibility.

BioNTech Earnings and Revenue Growth

BioNTech Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on BioNTech compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming BioNTech's revenue will decrease by 16.2% annually over the next 3 years.
The bearish analysts are not forecasting that BioNTech will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate BioNTech's profit margin will increase from -27.9% to the average US Biotechs industry of 16.4% in 3 years.
If BioNTech's profit margin were to converge on the industry average, you could expect earnings to reach €265.9 million (and earnings per share of €1.07) by about May 2028, up from €-766.0 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 108.5x on those 2028 earnings, up from -26.1x today. This future PE is greater than the current PE for the US Biotechs industry at 18.3x.
Analysts expect the number of shares outstanding to grow by 1.12% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.21%, as per the Simply Wall St company report.

BioNTech Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

BioNTech continues to experience declining revenue and expanding net losses as shown by a first quarter net loss of 416 million euros on only 183 million euros of revenue, driven by the sharp decline in COVID-19 vaccine sales and high R&D spending, which places significant pressure on earnings if new oncology products are delayed or underperform.
The company’s transformation into a multiproduct oncology business is largely dependent on late-stage clinical success and regulatory approvals for key candidates like BNT327 and BNT323; any delays, negative trial results, or setbacks in obtaining regulatory approval could significantly impair future revenues and profitability.
BioNTech’s ongoing reliance on China-based contract manufacturing organizations for key products exposes it to escalating geopolitical risks, such as future trade tariffs or disruptions to supply chains, which could elevate cost of goods sold and suppress net margins.
The potential narrowing of U.S. and global COVID-19 vaccine recommendations to high-risk populations, coupled with growing vaccine fatigue and mRNA skepticism in some regions, raises the likelihood of continued declines in COVID-19 vaccine revenues, which may not be offset in the short term by oncology product launches.
The advancement of competitor companies with overlapping clinical programs in mRNA therapeutics and immuno-oncology, and the risk of increased regulatory requirements or pricing pressures in major markets, could erode BioNTech’s future market share, limit pricing power, and reduce long-term projected margins and earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for BioNTech is $110.45, which represents the lowest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of BioNTech's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $171.7, and the most bearish reporting a price target of just $110.45.
In order for you to agree with the bearish analysts, you'd need to believe that by 2028, revenues will be €1.6 billion, earnings will come to €265.9 million, and it would be trading on a PE ratio of 108.5x, assuming you use a discount rate of 6.2%.
Given the current share price of $94.74, the bearish analyst price target of $110.45 is 14.2% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Losses And mRNA Risks Will Curtail Progress Yet Hint Recovery

Shared on07 May 25Fair value Increased 3.83%

Shared on30 Apr 25Fair value Decreased 2.21%

Shared on07 May 25
Fair value Increased 3.83%

Shared on30 Apr 25
Fair value Decreased 2.21%